Skip to main content
Have a personal or library account? Click to login
Testicular toxicity of Aroclor 1254 in selenium-deficient and selenium-supplemented rats Cover

Figures & Tables

Figure 1

Mean (±SD) body weights (A) and body weight gain in the first week (B) and the last 14 days (C) of treatment. a, b Bars that do not share same superscript letters are significantly different (p<0.05). A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS –Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 2

Mean (A) and relative (B) testis weights in our study groups. a, b, c Bars that do not share same superscript letters are significantly different (p<0.05). A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS –Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 3

Histopathological changes in the study groups: seminiferous tubules with normal morphology in control (A), SeS (B), SeD (C) and ASeS (E) groups; prominent degeneration of seminiferous epithelium in A1254 (D) and ASeD groups (F) (haematoxylin-eosin, 200× magnification). A1254 – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS –Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 4

TUNEL-positive (apoptotic) cells in seminiferous tubules of A) control; B) SeS; C) SeD; D) A1254; E) ASeS; and F) ASED group indicated by arrows (400× magnification) and G) mean (±SD) apoptotic cell counts across the groups. a, b, c, d Bars that do not share same superscript letters are significantly different (p<0.05). A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS – Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 5

Sperm images across the A) control; B) SeS; C) SeD; D) A1254; E) ASeS; and F) ASeD group. A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS – Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 6

Mean sperm count (A) and viability (B) across the study groups. a, b, c Bars that do not share same superscript letters are significantly different (p<0.05). A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS – Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 7

Mean prevalence of sperms with abnormal tails (%) across the study groups. a, b, c, d Bars that do not share same superscript letters are significantly different (p<0.05). A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS – Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 8

Mean oestradiol (A) and testosterone (B) levels across the study groups. a, b, c Bars that do not share same superscript letters are significantly different (p<0.05). A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS – Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Figure 9

Western blot for two samples of p21 and p53 proteins for each study group. A – Aroclor 1254 group receiving 0.15 mg/kg/day of Se for 5 weeks and 10 mg/kg/day of Aroclor 1254 in corn oil for the last 15 days; ASeD – Se-deficient group receiving Aroclor 1254 as described above.; ASeS – Se-supplemented group receiving Aroclor 1254 as described above; Control – group receiving 0.15 mg/kg/day of Se for 5 weeks; HepG2 – positive control cells; SeD – Se-deficient group receiving 0.50 mg/kg/day of Se for 5 weeks; SeS – Se-supplemented group receiving 1 mg selenium/kg/day for 5 weeks

Caspase-3 and caspase-8 activities across the study groups

Caspase-3 (µmol p-NA/min/mg protein)Caspase-8 (nmol p-NA/min/mg protein)
Control23.57±0.18a9.21±0.01a
SeS17.51±0.68a9.25±0.01a
SeD25.29±0.11a11.65±0.01b
A31.74±1.98b9.17±0.23a
ASeS22.18±1.31a8.96±0.01a
ASeD33.48±1.48b12.04±0.20b

Sperm morphologies across the study groups

ControlSeSSeDAASeSASeD
Normal sperm (%)71.4382.6948.4028.0654.6526.91
Sperms without tail (%)1.750.430.992.360.963.79
Sperms without head (%)5.754.308.1312.6010.3923.64
Sperms with rudimentary tail (%)0.480.000.371.841.583.92
Sperms with curved tail (%)14.376.1310.9646.4925.6234.49
Sperms with bend mid-piece (%)0.871.942.711.181.963.21
Sperms with coiled tail (%)5.241.835.307.484.844.05
Sperms with curved mid-piece (%)0.122.6923.150.000.000.00
Sperms with swapped tail (%)0.000.000.000.000.000.00
Total N of abnormal sperm (%)28.5717.3151.6059.9545.3573.09
Total N of sperm (%)100100100100100100

Antioxidant enzyme activities; antioxidant, lipid peroxidation, protein oxidation, and selenoprotein P levels and total antioxidant capacity in the study groups

GPx1 (U/mg protein)TrxR (U/mg protein)SOD (U/mg protein)CAT (nmol/min/mg protein)GSH (nmol/mg protein)MDA (nmol/mg protein)Carbonyl groups (nmol/mg protein)TAOC (nmol/mg protein)SePP (ng/µg protein)
Control0.12±0.01a0.19±0.02a0.13±0.01a3.71±0.22 ac3.32±0.24a1.42±0.04a0.72±0.04a25.27±0.60a7.25±0.64a
SeS0.14±0.01a0.25±0.01b0.14±0.02a4.04±0.26a3.67±0.14a1.34±0.15a0.63±0.08a26.69±1.46a8.59±1.65a
SeD0.06±0.01b0.12±0.02c0.11±0.01a2.97±0.15c1.75±0.04b1.55±0.07a0.75±0.04a26.15±0.53a4.31±0.74b
A0.10± 0.01c0.15±0.02c0.10±0.02b1.95±0.59b1.21±0.11c1.95±0.09b0.93±0.09b24.52±0.66a4.10±1.04b
ASeS0.13±0.01a0.19±0.02a0.12±0.01a3.75±0.2ac3.31±0.10a1.61±0.05a0.83±0.08a25.21±0.35a4.24±1.08b
ASeD0.08±0.02d0.11±0.02c0.09±0.01b2.10±0.19bc1.06±0.04c2.01±0.07b0.97±0.03b20.93±1.68b3.62±0.40b
DOI: https://doi.org/10.2478/aiht-2026-77-4027 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English
Page range: 102 - 113
Submitted on: Jul 1, 2025
Accepted on: May 1, 2026
Published on: Jun 30, 2026
In partnership with: Paradigm Publishing Services

© 2026 Pınar Erkekoğlu, Aylin Balcı-Özyurt, Naciye Dilara Zeybek, Hülya Tezel-Yalçın, Ünzile Yaman, Gizem Yildiztekin, Sevtap Aydın-Dilsiz, Murat Kızılgün, Evin İşcan, Tuğçe Batur, Mehmet Öztürk, Oğuz Han Edebal, Nurşen Başaran, Belma Koçer-Gumusel, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution 4.0 License.